Article
Dexmedetomidine attenuates lipopolysaccharide-induced renal cell fibrotic phenotypic changes by inhibiting necroinflammation via activating α2-adrenoceptor: A combined randomised animal and in vitro study.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 May 2024
Sun Qizhe, Kamath Priyanka, Sun Yibing, Liang Min, Wu Lingzhi, Chang Enqiang, Chen Qian, Alam Azeem, Liu Yi, Zhao Hailin, Ma Daqing
Abstract excerpt
BACKGROUND: Acute kidney injury (AKI) was reported to be one of the initiators of chronic kidney disease (CKD) development. Necroinflammation may contribute to the progression from AKI to CKD. Dexmedetomidine (Dex), a highly selective α2-adrenoreceptor (AR) agonist, has cytoprotective and "anti-" inflammation effects. This study was designed to investigate the anti-fibrotic properties of Dex in sepsis models....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.